ZytuxTM is a biosimilar product with the generic name of Rituximab. It is a genetically engineered human-mouse chimeric monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells in suspension. It is a fusion of the light and heavy chain variable domains of a murine monoclonal anti-CD20 antibody and human kappa light-chain and gamma 1 heavy-chain constant regions. Rituximab is a chimeric monoclonal antibody against CD20 antigens presents on surface of lymphocyte cells. Rituximab binds to the target CD20 antigen via the variable murine regions, while the remainder of the antibody interacts with human immune-effector mechanisms to kill the target cells.
Zytux™ is used for treatment of:
Non-Hodgkin’s Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid Arthritis (RA)
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
ZytuxTM is supplied as a sterile, clear and colorless concentrate for solution for infusion. It is provided in vials of 10 milliliter and 50 milliliter containing 100 mg and 500 mg Rituximab, respectively. Zytux™ should be administered as intravenous infusion after dilution.
Aryogen staff are happy with their job supporting advanced production systems and their needs.
Biopharmaceutical production applying cutting edge biotechnology practices and manufacturing technology transfer
Increasing the quality and availability of biopharmaceutical products in order to improve quality of life of global community
Achieving the first rank in development, production and export of biopharmaceuticals in the region over the next 5 years
Winning 5% of Iran's market share over the next 5 year